FY 2024 Trading Update
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your KMK notes
Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, provides the following update on trading for the 12-month period ended 30 April 2024.
As announced in its interim results, Kromek started the second half of FY 2024 with increasing commercial momentum whilst delivering on multi-year contracts. Both the advanced imaging and CBRN detection segments showed increased commercial traction and the Group expects to report record revenues for FY 2024.
Kromek is also experiencing improvements in its gross margin due to the product mix sold. The Group continues to exert tight cost control whilst driving further operational efficiencies, particularly within its advanced imaging manufacturing process. Consequently, Kromek expects to report positive EBITDA for FY 2024, and ahead of market expectations.
Further details will be provided at the time of the full year results, expected to be released in September 2024.
Kromek Group plc
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
Further information is available at www.kromek.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.